A Phase 3 interventional study of eltrombopag and placebo in Purpura, Thrombocytopenic, Idiopathic and Hepatitis C, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eltrombopag in Purpura — none open to participants now, none under way, none of them phase 3. eltrombopag · Purpura.
Among the 11 studies testing eltrombopag in Purpura, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 11th registered.
45 studies on the registry are indexed under Purpura; 4 are open to participants now.
Browse Purpura studies →None of the 11 studies testing eltrombopag in Purpura is open now. The open studies under Purpura, anywhere →
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 4 Purpura studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2013.
This study's enrollment of 155 is above the median of 79 across 34 interventional studies indexed under Purpura.
Median enrollment 82 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Purpura — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eltrombopag in Purpura, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects. This study was be conducted in Chinese adult chronic ITP subjects who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.
The primary objective of this study was to determine the efficacy of oral eltrombopag as a thrombopoietic agent treating previously treated chronic Chinese ITP patients compared to placebo. The secondary objective was to assess the safety and tolerability of eltrombopag when administered for 6 weeks to previously treated adult chronic ITP patients compared with placebo. In addition, the long-term efficacy and safety of eltrombopag treatment was also evaluated in the 24-week extension open-label phase after the double-blind phase as one of other study objectives. If the subject benefited from the eltrombopag treatment based on the investigator's discretion, the subject could continue on eltrombopag treatment until the commercial launch of eltrombopag in China. Furthermore, to understand the pharmacokinetics (PK) profile of eltrombopag and to explore the relationship between the PK and pharmacodynamics (PD) (platelet response), a PK/PD analysis was embedded in this phase III study and conducted in the same patient population who participated this phase III study.
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects. This study was conducted in Chinese adult chronic ITP subjects who had not responded to or had relapsed after previous treatment for ITP, including first line therapy and /or splenectomy.
The primary objective of this study was to determine the efficacy of oral eltrombopag as a thrombopoietic agent treating previously treated chronic Chinese ITP patients compared to placebo. The secondary objective was to assess the safety and tolerability of eltrombopag when administered for 6 weeks to previously treated adult chronic ITP patients compared to placebo. In addition, the long-term efficacy and safety of eltrombopag treatment was also evaluated in the 24-week extension open-label phase after the double-blind phase as one of other study objectives. If the subject benefited from the eltrombopag treatment based on the investigator's discretion, the subject could continue the eltrombopag treatment until the commercial launch of eltrombopag in China. Furthermore, to understand the pharmacokinetics (PK) profile of eltrombopag and to explore the relationship between the PK and pharmacodynamics (PD) (platelet response), a PK/PD analysis was embedded in this phase III study and conducted in the same patient population who participated this phase III study.
155 eligible subjects were randomized to either eltrombopag or matching placebo treatment in 2:1 ratio in stage 1 (the 8-week double blind stage). Randomization for stage 1 was stratified by splenectomy status (Yes/No), use of concomitant maintenance ITP therapy (Yes/No) and baseline platelet count (no more than 15×109/L, or >15×109/L). This study include 3 stages. The stage 1 was an 8-week double-blind, randomized, placebo-controlled treatment period. Following completion of Stage 1 and after completing the data cleanup of the initial 6 weeks, the investigator was be un-blinded to treatment assignment on an individual subject basis to enable appropriate starting dose selection for stage 2, a 24-week open-label treatment period. PK sampling and assessments occurred at the Week 2 visit during stage 2 of the study, when all subjects were receiving eltrombopag. After the completion of stage 2, subjects could continue the the eltrombopag treatment in stage 3, if he/she benefited from the continuous eltrombopag treatment based on the investigator's judgement.
The initial dose of eltrombopag administration was an oral 25 mg once daily. During the 8 weeks double-blind treatment, dose of investigational product was adjusted according to the weekly subject platelet count.
The eligible subjects who completed stage 1 (8 weeks of double-blind treatment period: the first 6 weeks data was used for primary endpoint analysis and the last 2 weeks for data cleanup period during which the blinded treatment continued) entered a voluntary open-label stage 2 (24-week open-label extension phase) in which subjects from both the eltrombopag group and placebo group had the opportunity to receive eltrombopag treatment. Subjects unwilling or unqualified (such as the subjects who met the stopping criteria) to participate in extension treatment attended follow-up visits for 4 weeks after the completion of the double-blind phase. During the open-label stage 2 phase all eligible subjects received open label eltrombopag treatment. The dose of eltrombopag was continuously adjusted according to the subject's platelet count.
Following completion of Stage 2, if the subject benefited from the eltrombopag treatment based on the investigator's discretion, the subject could voluntarily enter stage 3, during which the subject continued eltrombopag treatment until the commercial launch of eltrombopag in C
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A complete blood count (CBC), within the reference range, with the following exceptions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thrombopoietin- receptor (TPO-R) agonist
Drug: eltrombopag
Placebo
Drug: placebo
TPO-R agonist
Also known as: ETB115
placebo
Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L After the First 6 Weeks of Stage 1
The number of participants (responders) with platelet count \>=50x10\^9/L after 6 weeks of Stage 1 were compared between treatments using a logistic regression model adjusted for use of primary immune thrombocytopenia (ITP) medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Primary Analysis Data Set: a participant who withdrawals from Stage 1 or is emergently unblinded was classified as a negative response from the time of withdrawal or unblinding date and for all subsequent visits. In the event of a participant dying, information for all subsequent assessments would be considered missing. All intermittent missing data (apart from withdrawals) will be treated as missing.
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Number of Participants Achieving a Platelet Count >=50×10^9/L at Least Once During the First 6 Weeks of Stage 1
The number of participants (responders) with platelet count \>=50×10\^9/L at least once during the first 6 weeks of Stage 1 were compared between treatments using a logistic regression model adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Number of Participants Achieving a Platelet Count >=30×10^9/L and at Least 2 Times the Baseline Platelet Count at Least Once During the 6 Weeks of Stage 1, the Whole Stage 2 and the Whole Stage 3
The number of participants achieving a platelet count \>=30×10\^9/L and at least 2 times the Baseline platelet count at least once during the first 6 weeks of Stage 1 were analyzed. The Baseline platelet count is defined as the platelet count taken on Day 1 of the study or within 48 hours prior to the first dose of investigational product. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Number of Participants With Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. The WHO Bleeding Scale were dichotomized to indicate no bleeding vs bleeding, i.e. 0=grade 0 and 1=grades 1, 2, 3 or 4. Generalized linear mixed model was applied with a Logit canonical link function for repeated binary data, allowing for Baseline dichotomized WHO bleeding grade, use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment as fixed effects, and the participant was treated as a random effect. Bleeding incidences were recorded at Screening, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6 for Stage 1, Baseline, Weeks 4, 8, 16, 20, 24 for Stage 2; Baseline, Weeks 25, 29, 73, 97, 121, 145, 169, 193, 217, 241, 265, 284 for Stage 3. Bleeding incidences at these time points are presented.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Number of Participants With Clinically Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. The WHO Bleeding Scale grades were dichotomized into the following categories: no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4. Generalized linear mixed model with a Logit canonical link function for repeated binary data, allowing for Baseline dichotomized WHO bleeding grade, use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment as fixed effects, and the participant was treated as a random effect.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Time to Response
Time to response is defined as time from the startin of treatment to the first time of achieving a platelet count \>=50x10\^9/L during the first 6 weeks of Stage 1. Time to response is summarized using Kaplan-Meier estimates and compared between treatment groups using a stratified log-rank test, stratifying for the use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no). The pike estimator of the treatment hazard ratio is based on the stratified log-rank test. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Number of Participants Who Required Protocol-defined Rescue Treatment During the First 6 Weeks of Stage 1, Whole Stages 2 & 3
Rescue treatment is defined as either a new ITP medication, an increase in dose of concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no) and treatment.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Number of Participants With a Platelet Count >=50×10^9/L During at Least 75% of Their Platelet Count Assessments
The number of participants with a platelet count \>=50×10\^9/L during at least 75% of their platelet count assessments was analyzed up to the end of Week 6 of Stage 1. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Total Duration of Time a Participant Had a Platelet Count >=50×10^9/L
Total duration of time a participant had platelet count \>=50 x 10\^9/L was analyzed using the van Elteren stratified rank test with stratification factors including the use of ITP medication at Baseline (yes/no), splenectomy (yes/no) and Baseline platelet count \<=15x10\^9/L (yes/no). Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Maximum Period of Time a Participant Had a Platelet Count Continuously >= 50 ×10^9/L
Maximum period of time a participant had a platelet count continously \>=50 x 10\^9/L was analyzed using the van Elteren stratified rank test with stratification factors including the use of ITP medication at Baseline (yes/no), splenectomy (yes/no) and Baseline platelet count \<=15x10\^9/L (yes/no). Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
Time frame: From the start of study treatment (Day 1) up to the end of Stage 3
Number of Participants That Reduced or Discontinued Baseline Concomitant ITP Medications During Stage 2 and Stage 3
The number of participants taking concomitant ITP medications on Day 1 of Stage 1 who had a decrease in the dose or frequency of ITP medication or stopped ITP medication at any point during Stage 2 or Stage 3 will be presented. The Baseline concomitant ITP medication for Stage 2 and Stage 3 is defined as ITP medications taken prior to the first dose of investigational product of Stage 1. This study is still ongoing and this endpoint can only be analyzed when the stage 2 and stage 3 complete.
Time frame: From the start of Stage 2 to the end of Stage 3
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, is a congenital anomaly/birth defect or is associated with protocol specified liver injury and impaired liver function or is any protocol specific AEs.
Time frame: From the start of study treatment (Day 1) up to the end of Week 8 of Stage 1
Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters
Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), gamma glutamyl transferase (GGT), total bilirubin, albumin, alkaline phosphatase, calcium, potassium, creatinine, glucose and sodium were evaluated at Baseline, at all on therapy visits, and at Week 1, Week 2, Week 3, and Week 4 visits during the follow-up period and were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (NCI CTCAE V4.0): Grade 0, none; Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant; Grade 4, life-threatening consequences; Grade 5, death related to AE. Day 1 assessment was considered as Baseline; if Day 1 was not available then Screening assessment is taken as Baseline. For creatinine, Baseline is defined as the average of Screening and Day 1 values if available and prior to first dose. Maximum post-Baseline toxicity grade included any scheduled or unscheduled post-Baseline assessment
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Number of Participants With the Maximum Toxicity Grade for the Indicated Hematology Parameters
Clinical hematology parameters hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell count evaluations were performed at Baseline, at all on-therapy visits, and at Week 1, Week 2, Week 3, and Week 4 visits during the follow-up period and were summarized according to the NCI CTCAE V4.0: Grade 0, none; Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant; Grade 4, life-threatening consequences; Grade 5, death related to AE. Day 1 assessment was considered as Baseline; if Day 1 was not available then Screening assessment is taken as Baseline. Maximum post-Baseline toxicity grade included any scheduled or unscheduled post-Baseline assessment.
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Change From Baseline in Systolic Blood Pressure
Systolic blood pressure was measured in the sitting position at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6
Change From Baseline in Diastolic Blood Pressure
Diastolic blood pressure was measured in sitting position at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6
Change From Baseline in Pulse Rate
Pulse rate was measured at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6
Number of Participants With the Indicated 12-lead Electrocardiogram (ECG) Finding at Baseline
Resting 12-lead ECG was obtained at Baseline. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. ECG was also obtained when there was clinical symptom that potentially related to cardiac dysfunction based on investigator's judgement.
Time frame: Baseline
Number of Participants With a Change From Baseline in Visual Acuity
Visual acuity is a measure of the spatial resolution of the visual processing system. Acuity is a measure of visual performance and is unrelated to the eyeglass prescription required to correct vision. Normal visual acuity is commonly referred to as 20/20 vision. Evaluation was done for oculus sinister (OS) for the left eye, oculus dexter (OD) for the right eye. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
Time frame: From the start of study treatment (Day 1) up to the end of Week 6 of Stage 1
Number of Participants With the Indicated Grading of Myelofibrosis Using Bone Marrow Biopsy at Screening
Bone marrow biopsy was performed at Screening and then obtained when clinically indicated. Whenever a peripheral blood smear confirmed the presence of immature or dysplastic cells, a bone marrow examination was performed. Myelofibrosis (MF) was graded from Grade MF-0 to MF-3 where MF-0=scattered linear reticulin with no intersections (cross-overs) corresponding to normal bone marrow; MF-1=loose network of reticulin with many intersections; especially in perivascular areas; MF-2=diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3=diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis.
Time frame: Screening
Pharmacokinetic (PK) Assessments for Eltrombopag for Apparent Volume of Distribution of Central Compartment (Vc/F), Apparent Volume of Distribution of Peripheral Compartment (Vp/F)
Vc/F is apparent volume of distribution of plasma (VDP) in central compartment and Vp/F is apparent VDP in peripheral compartment. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hr prior to dosing, all other samples were collected within 10 minutes(min) for samples collected between 1 and 6 hrs and within 30 mins for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameters are presented.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacokinetic Assessments for Eltrombopag for Apparent Clearance (CL/F), Apparent Inter-compartmental Clearance (Q/F)
CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hr prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hr and within 30 min for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameters are presented.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacokinetic Assessments for Eltrombopag for Absorption Rate Constant (Ka)
Ka is defined as the absorption rate constant. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hrs prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hrs and within 30 mins for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameter is presented.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacokinetic Assessments for Eltrombopag for Absorption Lag Time (ALAG)
Absorption lag time (ALAG) is defined as the time taken for a drug to appear in the systemic circulation following administration. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hrs and 5 to 8 hrs post-dose\]. Pre-dose samples were collected within 2 hrs prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hr and within 30 min for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameter is presented.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Post-hoc Estimates of Plasma Eltrombopag Area Under the Concentration-time Curve Over a Dosing Interval (AUC[0-tau]) After 50 mg Once Daily Dose of Eltrombopag
AUC\[0-tau\] is defined as area under the concentration-time curve over a dosing interval (24 hr) of Eltrombopag atsteady-state after 50 mg once daily dose of eltrombopag. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Post-hoc estimates of steady-state eltrombopag was determined based on the final PK model. Individual PK parameters were derived from the final PK model by an empirical Bayes estimation. Summary of steady-state AUC(0-tau) of eltrombopag is presented here.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Post-hoc Estimates of Maximum Observed Concentration (Cmax) for Eltrombopag After 50 mg Once Daily Dose of Eltrombopag
Cmax is defined as maximum observed concentration after 50 mg once daily dose of eltrombopag. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Post-hoc estimates of steady-state eltrombopag Cmax was determined based on the final PK model. Individual PK parameters were derived from the final PK model by an empirical Bayes estimation. Summary of steady-state Cmax of eltrombopag .is presented here.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Percentage of Participants Estimated as Responders to Eltrombopag by the Pharmacokinetic/ Pharmacodynamic Model
Responders are participants whose SLOP estimates are larger than zero. The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacodynamic Parameter-Linear Proportionality Constant of Drug Effect (SLOP): the Proportional Increase of Platelet Production Rate With Each 1-μg/mL Increase in Eltrombopag Plasma Concentration
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacodynamic Parameter- Production Rate of Platelet Precursors (KIN)
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment. The estimate of KIN was fixed to 1.43x10\^9/L.hr.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
Pharmacodynamic Parameter-Maturation Rate of Platelet Precursors (KOUT)
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment. The estimate of KOUT was fixed to 0.0253 /hr.
Time frame: From the start of study until 24 hours post-dose of Week 2 Visit of Stage 2
This study includes three stages: 8-week double-blind stage (Stage 1), 24-week open-label stage (Stage 2) and prolonged open-label stage (Stage 3) with voluntary participation until eltrombopag became commercially available in China. Final Results for this study are presented in this report.
| Milestone | Placebo | Eltrombopag |
|---|---|---|
| Started | 51 | 104 |
| Completed | 12 | 39 |
| Not completed | 39 | 65 |
| Withdrew: Adverse event | 15 | 17 |
| Withdrew: Lack of efficacy | 9 | 25 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Study closed/terminated | 0 | 2 |
| Withdrew: Lost to follow-up | 3 | 6 |
| Withdrew: Physician decision | 4 | 6 |
| Withdrew: Withdrawal by subject | 7 | 8 |
The number of participants (responders) with platelet count \>=50x10\^9/L after 6 weeks of Stage 1 were compared between treatments using a logistic regression model adjusted for use of primary immune thrombocytopenia (ITP) medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Primary Analysis Data Set: a participant who withdrawals from Stage 1 or is emergently unblinded was classified as a negative response from the time of withdrawal or unblinding date and for all subsequent visits. In the event of a participant dying, information for all subsequent assessments would be considered missing. All intermittent missing data (apart from withdrawals) will be treated as missing.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L After the First 6 Weeks of Stage 1 | 3 | 60 |
The number of participants (responders) with platelet count \>=50×10\^9/L at least once during the first 6 weeks of Stage 1 were compared between treatments using a logistic regression model adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Number of Participants Achieving a Platelet Count >=50×10^9/L at Least Once During the First 6 Weeks of Stage 1 | 9 | 80 |
The number of participants achieving a platelet count \>=30×10\^9/L and at least 2 times the Baseline platelet count at least once during the first 6 weeks of Stage 1 were analyzed. The Baseline platelet count is defined as the platelet count taken on Day 1 of the study or within 48 hours prior to the first dose of investigational product. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1 (during the first 6 weeks) | 18 | 84 |
| Stage 2 (during 24 weeks) | 45 | 81 |
| Stage 3 | 36 | 72 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. The WHO Bleeding Scale were dichotomized to indicate no bleeding vs bleeding, i.e. 0=grade 0 and 1=grades 1, 2, 3 or 4. Generalized linear mixed model was applied with a Logit canonical link function for repeated binary data, allowing for Baseline dichotomized WHO bleeding grade, use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment as fixed effects, and the participant was treated as a random effect. Bleeding incidences were recorded at Screening, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6 for Stage 1, Baseline, Weeks 4, 8, 16, 20, 24 for Stage 2; Baseline, Weeks 25, 29, 73, 97, 121, 145, 169, 193, 217, 241, 265, 284 for Stage 3. Bleeding incidences at these time points are presented.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1: Baseline | 36 | 68 |
| Stage 1: Week 1 | 30 | 43 |
| Stage 1: Week 2 | 27 | 32 |
| Stage 1: Week 3 | 26 | 29 |
| Stage 1: Week 4 | 24 | 23 |
| Stage 1: Week 5 | 19 | 24 |
| Stage 1: Week 6 | 17 | 17 |
| Stage 2: Baseline | 22 | 64 |
| Stage 2: Week 4 | 8 | 7 |
| Stage 2: Week 8 | 6 | 12 |
| Stage 2: Week 16 | 5 | 8 |
| Stage 2: Week 20 | 3 | 1 |
| Stage 2: Week 24 | 3 | 6 |
| Stage 3: Baseline | 16 | 49 |
| Stage 3: Week 25 | 14 | 19 |
| Stage 3: Week 29 | 1 | 1 |
| Stage 3: Week 73 | 1 | 3 |
| Stage 3: Week 97 | 1 | 1 |
| Stage 3: Week 121 | 1 | 0 |
| Stage 3: Week 145 | 0 | 1 |
| Stage 3: Week 169 | 1 | 0 |
| Stage 3: Week 193 | 0 | 0 |
| Stage 3: Week 217 | 2 | 2 |
| Stage 3: Week 241 | — | 0 |
| Stage 3: Week 265 | — | 0 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. The WHO Bleeding Scale grades were dichotomized into the following categories: no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4. Generalized linear mixed model with a Logit canonical link function for repeated binary data, allowing for Baseline dichotomized WHO bleeding grade, use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15×10\^9/L (yes/no) and treatment as fixed effects, and the participant was treated as a random effect.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1: Baseline | 5 | 14 |
| Stage 1:Week 1 | 5 | 12 |
| Stage 1: Week 2 | 4 | 13 |
| Stage 1: Week 3 | 6 | 11 |
| Stage 1: Week 4 | 5 | 7 |
| Stage 1: Week 5 | 2 | 8 |
| Stage 1: Week 6 | 4 | 6 |
| Stage 2: Baseline | 3 | 13 |
| Stage 2: Week 4 | 1 | 0 |
| Stage 2: Week 8 | 0 | 1 |
| Stage 2: Week 16 | 1 | 1 |
| Stage 2: Week 20 | 1 | 0 |
| Stage 2: Week 24 | 0 | 0 |
| Stage 3: Baseline | 1 | 9 |
| Stage 3: Week 25 | 1 | 0 |
| Stage 3: Week 29 | 1 | 0 |
| Stage 3: Week 73 | 0 | 0 |
| Stage 3: Week 97 | 0 | 0 |
| Stage 3: Week 121 | 0 | 0 |
| Stage 3: Week 145 | — | 0 |
| Stage 3: Week 169 | 0 | 0 |
| Stage 3: Week 193 | 0 | 0 |
| Stage 3: Week 217 | 0 | 0 |
| Stage 3: Week 241 | — | 0 |
| Stage 3: Week 265 | — | 0 |
| Stage 3: Week 286 | 0 | — |
Time to response is defined as time from the startin of treatment to the first time of achieving a platelet count \>=50x10\^9/L during the first 6 weeks of Stage 1. Time to response is summarized using Kaplan-Meier estimates and compared between treatment groups using a stratified log-rank test, stratifying for the use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no). The pike estimator of the treatment hazard ratio is based on the stratified log-rank test. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Weeks | Placebo | Eltrombopag |
|---|---|---|
| Time to Response | NA (NA to NA) | 3.14 (3.00 to 4.14) |
Rescue treatment is defined as either a new ITP medication, an increase in dose of concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no) and treatment.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1 (first 6 weeks) | 17 | 9 |
| Stage 2 | 16 | 14 |
| Stage 3 | 13 | 21 |
The number of participants with a platelet count \>=50×10\^9/L during at least 75% of their platelet count assessments was analyzed up to the end of Week 6 of Stage 1. Logistic regression analysis was adjusted for use of ITP medication at Baseline (yes/no), splenectomy (yes/no), Baseline platelet count \<=15x10\^9/L (yes/no) and treatment. Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1 (first 6 weeks) | 1 | 23 |
| Stage 2 | 10 | 38 |
| Stage 3 | 13 | 30 |
Total duration of time a participant had platelet count \>=50 x 10\^9/L was analyzed using the van Elteren stratified rank test with stratification factors including the use of ITP medication at Baseline (yes/no), splenectomy (yes/no) and Baseline platelet count \<=15x10\^9/L (yes/no). Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Weeks | Placebo | Eltrombopag |
|---|---|---|
| Stage 1 (first 6 weeks) | 0.00 (0.00 to 5.1) | 1.79 (0.14 to 5.1) |
| Stage 2 | 4.07 (0.0 to 23.3) | 7.29 (0.0 to 24.6) |
| Stage 3 | 27.00 (0.0 to 227.4) | 43.71 (0.0 to 224.0) |
Maximum period of time a participant had a platelet count continously \>=50 x 10\^9/L was analyzed using the van Elteren stratified rank test with stratification factors including the use of ITP medication at Baseline (yes/no), splenectomy (yes/no) and Baseline platelet count \<=15x10\^9/L (yes/no). Complete blood count including platelet count was done at Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6.
| Weeks | Placebo | Eltrombopag |
|---|---|---|
| Stage 1 (first 6 weeks) | 0.00 (0.00 to 0.00) | 1.57 (0.14 to 3.07) |
| Stage 2 | 2.71 (0.0 to 23.3) | 5.00 (0.0 to 24.6) |
| Stage 3 | 16.43 (0.0 to 227.1) | 28.14 (0.0 to 227.1) |
The number of participants taking concomitant ITP medications on Day 1 of Stage 1 who had a decrease in the dose or frequency of ITP medication or stopped ITP medication at any point during Stage 2 or Stage 3 will be presented. The Baseline concomitant ITP medication for Stage 2 and Stage 3 is defined as ITP medications taken prior to the first dose of investigational product of Stage 1. This study is still ongoing and this endpoint can only be analyzed when the stage 2 and stage 3 complete.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 2 | 19 | 20 |
| Stage 3 | 5 | 16 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, is a congenital anomaly/birth defect or is associated with protocol specified liver injury and impaired liver function or is any protocol specific AEs.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Stage 1: Any AE | 34 | 66 |
| Stage 1: Any SAE | 5 | 5 |
| Stage 2: Any AE | 43 | 64 |
| Stage 2: Any SAE | 6 | 11 |
| Stage 3: any AE | 38 | 70 |
| Stage 3: Any SAE | 11 | 21 |
Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), gamma glutamyl transferase (GGT), total bilirubin, albumin, alkaline phosphatase, calcium, potassium, creatinine, glucose and sodium were evaluated at Baseline, at all on therapy visits, and at Week 1, Week 2, Week 3, and Week 4 visits during the follow-up period and were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (NCI CTCAE V4.0): Grade 0, none; Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant; Grade 4, life-threatening consequences; Grade 5, death related to AE. Day 1 assessment was considered as Baseline; if Day 1 was not available then Screening assessment is taken as Baseline. For creatinine, Baseline is defined as the average of Screening and Day 1 values if available and prior to first dose. Maximum post-Baseline toxicity grade included any scheduled or unscheduled post-Baseline assessment
| Participants | Placebo | Eltrombopag |
|---|---|---|
| AST, Grade 1 | 8 | 10 |
| AST, Grade 2 | 0 | 2 |
| AST, Grade 3 | 0 | 0 |
| AST, Grade 4 | 0 | 0 |
| AST, Grade 5 | 0 | 0 |
| ALT, Grade 1 | 11 | 14 |
| ALT, Grade 2 | 2 | 1 |
| ALT, Grade 3 | 1 | 1 |
| ALT, Grade 4 | 0 | 0 |
| ALT, Grade 5 | 0 | 0 |
| GGT,Grade 1 | 10 | 10 |
| GGT,Grade 2 | 2 | 2 |
| GGT,Grade 3 | 0 | 0 |
| GGT,Grade 4 | 0 | 0 |
| GGT,Grade 5 | 0 | 0 |
| Total Bilirubin, Grade 1 | 2 | 17 |
| Total Bilirubin, Grade 2 | 0 | 1 |
| Total Bilirubin, Grade 3 | 0 | 0 |
| Total Bilirubin, Grade 4 | 0 | 0 |
| Total Bilirubin, Grade 5 | 0 | 0 |
| Albumin, Grade 1 | 2 | 10 |
| Albumin, Grade 2 | 1 | 2 |
| Albumin, Grade 3 | 0 | 0 |
| Albumin, Grade 4 | 0 | 0 |
| Albumin, Grade 5 | 0 | 0 |
| Alkaline Phosphatase, Grade 1 | 1 | 8 |
| Alkaline Phosphatase, Grade 2 | 0 | 0 |
| Alkaline Phosphatase, Grade 3 | 0 | 0 |
| Alkaline Phosphatase, Grade 4 | 0 | 0 |
| Alkaline Phosphatase, Grade 5 | 0 | 0 |
| Calcium, Grade 1 | 4 | 16 |
| Calcium, Grade 2 | 5 | 13 |
| Calcium, Grade 3 | 0 | 0 |
| Calcium, Grade 4 | 0 | 0 |
| Calcium, Grade 5 | 0 | 0 |
| Potassium, Grade 1 | 25 | 25 |
| Potassium, Grade 2 | 0 | 1 |
| Potassium, Grade 3 | 1 | 7 |
| Potassium, Grade 4 | 0 | 0 |
| Potassium, Grade 5 | 0 | 0 |
| Creatinine, Grade 1 | 0 | 2 |
| Creatinine, Grade 2 | 0 | 0 |
| Creatinine, Grade 3 | 0 | 0 |
| Creatinine, Grade 4 | 0 | 1 |
| Creatinine, Grade 5 | 0 | 0 |
| Glucose, Grade 1 | 14 | 34 |
| Glucose, Grade 2 | 4 | 13 |
| Glucose, Grade 3 | 2 | 2 |
| Glucose, Grade 4 | 0 | 0 |
| Glucose, Grade 5 | 0 | 0 |
| Sodium, Grade 1 | 10 | 19 |
| Sodium, Grade 2 | 0 | 0 |
| Sodium, Grade 3 | 0 | 1 |
| Sodium, Grade 4 | 0 | 0 |
| Sodium, Grade 5 | 0 | 0 |
Clinical hematology parameters hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell count evaluations were performed at Baseline, at all on-therapy visits, and at Week 1, Week 2, Week 3, and Week 4 visits during the follow-up period and were summarized according to the NCI CTCAE V4.0: Grade 0, none; Grade 1, mild; Grade 2, moderate; Grade 3, severe or medically significant; Grade 4, life-threatening consequences; Grade 5, death related to AE. Day 1 assessment was considered as Baseline; if Day 1 was not available then Screening assessment is taken as Baseline. Maximum post-Baseline toxicity grade included any scheduled or unscheduled post-Baseline assessment.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| Hemoglobin, Grade 1 | 21 | 35 |
| Hemoglobin, Grade 2 | 1 | 11 |
| Hemoglobin, Grade 3 | 3 | 4 |
| Hemoglobin, Grade 4 | 0 | 0 |
| Hemoglobin, Grade 5 | 0 | 0 |
| Lymphocytes, Grade 1 | 0 | 2 |
| Lymphocytes, Grade 2 | 12 | 16 |
| Lymphocytes, Grade 3 | 0 | 1 |
| Lymphocytes, Grade 4 | 0 | 0 |
| Lymphocytes, Grade 5 | 0 | 0 |
| Platelet count, Grade 1 | 1 | 1 |
| Platelet count, Grade 2 | 0 | 11 |
| Platelet count, Grade 3 | 5 | 26 |
| Platelet count, Grade 4 | 44 | 66 |
| Platelet count, Grade 5 | 0 | 0 |
| Total Neutrophils, Grade 1 | 5 | 7 |
| Total Neutrophils, Grade 2 | 3 | 3 |
| Total Neutrophils, Grade 3 | 0 | 0 |
| Total Neutrophils, Grade 4 | 0 | 0 |
| Total Neutrophils, Grade 5 | 0 | 0 |
| White Blood Cell Count, Grade 1 | 4 | 9 |
| White Blood Cell Count, Grade 2 | 1 | 2 |
| White Blood Cell Count, Grade 3 | 0 | 0 |
| White Blood Cell Count, Grade 4 | 0 | 0 |
| White Blood Cell Count, Grade 5 | 0 | 0 |
Systolic blood pressure was measured in the sitting position at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
| Millimeters of mercury (mm Hg) | Placebo | Eltrombopag |
|---|---|---|
| Week 1 | -0.3 ± 8.86 | -0.7 ± 12.65 |
| Week 2 | -2.0 ± 9.83 | -0.2 ± 14.08 |
| Week 3 | 0.3 ± 12.61 | -1.5 ± 14.05 |
| Week 4 | -0.2 ± 13.24 | -2.7 ± 14.37 |
| Week 5 | -3.0 ± 12.02 | -2.8 ± 12.57 |
| Week 6 | -1.5 ± 13.25 | -2.3 ± 13.62 |
Diastolic blood pressure was measured in sitting position at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
| mm Hg | Placebo | Eltrombopag |
|---|---|---|
| Week 1 | -0.3 ± 6.66 | -0.5 ± 8.90 |
| Week 2 | -1.1 ± 8.01 | -0.1 ± 10.91 |
| Week 3 | -1.0 ± 7.16 | -1.5 ± 10.40 |
| Week 4 | -0.9 ± 8.51 | -1.4 ± 9.57 |
| Week 5 | -3.0 ± 8.39 | -1.8 ± 9.78 |
| Week 6 | -2.2 ± 9.44 | -1.0 ± 9.71 |
Pulse rate was measured at Baseline, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
| Beats per minute | Placebo | Eltrombopag |
|---|---|---|
| Week 1 | -0.5 ± 6.88 | 0.2 ± 8.54 |
| Week 2 | -2.2 ± 9.23 | 0.2 ± 9.54 |
| Week 3 | 1.6 ± 10.31 | 0.2 ± 8.79 |
| Week 4 | -0.1 ± 7.32 | 0.8 ± 8.52 |
| Week 5 | 0.0 ± 9.06 | 0.0 ± 7.32 |
| Week 6 | -2.1 ± 8.55 | 0.1 ± 8.06 |
Resting 12-lead ECG was obtained at Baseline. Day 1 assessment was considered as Baseline; if Day 1 was not available then the Screening assessment was considered as Baseline. ECG was also obtained when there was clinical symptom that potentially related to cardiac dysfunction based on investigator's judgement.
| Particpants | Placebo | Eltrombopag |
|---|---|---|
| Normal | 36 | 57 |
| Abnormal, not clinically significant | 14 | 43 |
| Abnormal, clinically significant | 0 | 4 |
Visual acuity is a measure of the spatial resolution of the visual processing system. Acuity is a measure of visual performance and is unrelated to the eyeglass prescription required to correct vision. Normal visual acuity is commonly referred to as 20/20 vision. Evaluation was done for oculus sinister (OS) for the left eye, oculus dexter (OD) for the right eye. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| OD | 24 | 33 |
| OS | 22 | 35 |
Bone marrow biopsy was performed at Screening and then obtained when clinically indicated. Whenever a peripheral blood smear confirmed the presence of immature or dysplastic cells, a bone marrow examination was performed. Myelofibrosis (MF) was graded from Grade MF-0 to MF-3 where MF-0=scattered linear reticulin with no intersections (cross-overs) corresponding to normal bone marrow; MF-1=loose network of reticulin with many intersections; especially in perivascular areas; MF-2=diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3=diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis.
| Participants | Placebo | Eltrombopag |
|---|---|---|
| MF Score 0 | 38 | 83 |
| MF Score 1 | 13 | 19 |
| MF Score 2 | 0 | 0 |
| MF Score 3 | 0 | 0 |
Vc/F is apparent volume of distribution of plasma (VDP) in central compartment and Vp/F is apparent VDP in peripheral compartment. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hr prior to dosing, all other samples were collected within 10 minutes(min) for samples collected between 1 and 6 hrs and within 30 mins for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameters are presented.
| Liters | Eltrombopag |
|---|---|
| Vc/F | 8.80 (7.84 to 9.76) |
| Vp/F | 33.6 (17.0 to 50.2) |
CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hr prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hr and within 30 min for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameters are presented.
| Liters per hour(L/hr) | Eltrombopag |
|---|---|
| CL/F | 0.370 (0.336 to 0.404) |
| Q/F | 0.561 (0.444 to 0.678) |
Ka is defined as the absorption rate constant. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hr and 5 to 8 hr post-dose\]. Pre-dose samples were collected within 2 hrs prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hrs and within 30 mins for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameter is presented.
| Per hour (1/hr) | Eltrombopag |
|---|---|
| Pharmacokinetic Assessments for Eltrombopag for Absorption Rate Constant (Ka) | 1.58 (1.05 to 2.11) |
Absorption lag time (ALAG) is defined as the time taken for a drug to appear in the systemic circulation following administration. PK assessments were made with one group of serial sampling \[Samples collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24 hr post-dose\] and one group of sparse assessment \[Samples collected at pre-dose, between 2 to 4 hrs and 5 to 8 hrs post-dose\]. Pre-dose samples were collected within 2 hrs prior to dosing, all other samples were collected within 10 min for samples collected between 1 and 6 hr and within 30 min for samples collected at 8 and 24 hr. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Point estimates of population PK parameter is presented.
| Hour | Eltrombopag |
|---|---|
| Pharmacokinetic Assessments for Eltrombopag for Absorption Lag Time (ALAG) | 0.855 (0.816 to 0.894) |
AUC\[0-tau\] is defined as area under the concentration-time curve over a dosing interval (24 hr) of Eltrombopag atsteady-state after 50 mg once daily dose of eltrombopag. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Post-hoc estimates of steady-state eltrombopag was determined based on the final PK model. Individual PK parameters were derived from the final PK model by an empirical Bayes estimation. Summary of steady-state AUC(0-tau) of eltrombopag is presented here.
| Microgram* hour per milliliter(μg.hr/mL) | Eltrombopag |
|---|---|
| Post-hoc Estimates of Plasma Eltrombopag Area Under the Concentration-time Curve Over a Dosing Interval (AUC[0-tau]) After 50 mg Once Daily Dose of Eltrombopag | 88.8 (78.0 to 101) |
Cmax is defined as maximum observed concentration after 50 mg once daily dose of eltrombopag. PK analysis was conducted using a population approach with non-linear mixed effects modeling methods. Post-hoc estimates of steady-state eltrombopag Cmax was determined based on the final PK model. Individual PK parameters were derived from the final PK model by an empirical Bayes estimation. Summary of steady-state Cmax of eltrombopag .is presented here.
| Nanogram/ Milliliter (ng/mL) | Eltrombopag |
|---|---|
| Post-hoc Estimates of Maximum Observed Concentration (Cmax) for Eltrombopag After 50 mg Once Daily Dose of Eltrombopag | 6916 (6205 to 7708) |
Responders are participants whose SLOP estimates are larger than zero. The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment.
| Percentage of participants | Eltrombopag |
|---|---|
| Percentage of Participants Estimated as Responders to Eltrombopag by the Pharmacokinetic/ Pharmacodynamic Model | 89 |
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment.
| Milliliter/microgram | Eltrombopag |
|---|---|
| Pharmacodynamic Parameter-Linear Proportionality Constant of Drug Effect (SLOP): the Proportional Increase of Platelet Production Rate With Each 1-μg/mL Increase in Eltrombopag Plasma Concentration | 0.860 (0.639 to 1.08) |
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment. The estimate of KIN was fixed to 1.43x10\^9/L.hr.
| 1 x 10^9/L.hr | Eltrombopag |
|---|---|
| Pharmacodynamic Parameter- Production Rate of Platelet Precursors (KIN) | 1.43 |
The Pharmacokinetic/ Pharmacodynamic relationship between eltrombopag concentrations and the platelet response was described by a four-compartment life span model, representing one precursor production compartment, two transit/maturation compartments and one blood platelet compartment. The estimate of KOUT was fixed to 0.0253 /hr.
| 1/ hr | Eltrombopag |
|---|---|
| Pharmacodynamic Parameter-Maturation Rate of Platelet Precursors (KOUT) | 0.0253 |
Collected over Adverse Event (AE) timeframe: Adverse events were collected from study start (form first dose of study treatment) until end of study treatment plus 30 days post-treatment, up to a maximum duration of approx. 70 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 3/51 (5.9%) | 17/51 (33.3%) | 48/51 (94.1%) |
| Eltrombopag | 0/104 (0%) | 33/104 (31.7%) | 90/104 (86.5%) |
| Event | Placebo | Eltrombopag |
|---|---|---|
| PLATELET COUNT DECREASEDInvestigations | 4/51 | 1/104 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 2/51 | 3/104 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 2/51 | 0/104 |
| DEATHGeneral disorders | 2/51 | 0/104 |
| CATARACTEye disorders | 1/51 | 4/104 |
| CEREBRAL INFARCTIONNervous system disorders | 1/51 | 4/104 |
| LENTICULAR OPACITIESEye disorders | 1/51 | 0/104 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/51 | 0/104 |
| INTUSSUSCEPTIONGastrointestinal disorders | 1/51 | 0/104 |
| GASTROENTERITISInfections and infestations | 1/51 | 0/104 |
| Event | Placebo | Eltrombopag |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 21/51 | 28/104 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 13/51 | 39/104 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 19/51 | 26/104 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 18/51 | 22/104 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 14/51 | 20/104 |
| URINARY TRACT INFECTIONInfections and infestations | 13/51 | 19/104 |
| BLOOD BILIRUBIN UNCONJUGATED INCREASEDInvestigations | 10/51 | 10/104 |
| BLOOD BILIRUBIN INCREASEDInvestigations | 9/51 | 19/104 |
| ANAEMIABlood and lymphatic system disorders | 9/51 | 17/104 |
| DIARRHOEAGastrointestinal disorders | 8/51 | 11/104 |
| Age, Continuous(Years) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| Mean | 41.3 ± 12.83 | 44.7 ± 15.91 | 43.6 ± 15.01 |
| Sex: Female, Male(Participants) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| Female | 40 | 77 | 117 |
| Male | 11 | 27 | 38 |
| Race/Ethnicity, Customized(Participants) | Placebo | Eltrombopag | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 51 | 104 | 155 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Feb 2013 to primary completion in Jun 2014, 15 months.
Results were first posted in Mar 2015, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag